Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease
Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model
Objective: Levodopa (LD) is the standard treatment for Parkinson’s Disease (PD) despite risk of LD-induced dyskinesia (LID) development within a decade of treatment. Serotonergic (5-HT)…Trends in Physiotherapy Interventions and Medical Costs for Parkinson’s Disease in South Korea, 2011–2020
Objective: We analyzed trends in PT interventions and associated medical costs among South Korean patients with PD between 2011 and 2020. Background: Physiotherapy (PT), an…Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film
Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…Moderators of aerobic exercise effects on motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis
Objective: To investigate the difference in the effects of aerobic exercise on motor function in patients with Parkinson's disease (PD) according to exercise intervention protocols.…Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease
Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion
Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs
Objective: To evaluate the membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD iPSCs in the presence and absence of extracellular α-Synuclein. Background:…A novel single-cell reporter identifies regulators of the endogenous PINK1-Parkin mitochondrial quality control pathway
Objective: We aimed to identify genome-wide regulators of the PINK1-Parkin pathway using a novel flow cytometry reporter, endogenously tagged MFN2, as a readout of the…Discriminating alpha-synuclein strains in Parkinson’s disease
Objective: To evaluate possible differences in the biological properties of alpha-synuclein fibrils derived from different patients with Parkinson's disease. Background: Parkinson’s disease (PD) is a…
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 181
- Next Page »